| Literature DB >> 26828589 |
Federica Viti1,2, Martina Landini2, Alessandra Mezzelani2, Loredana Petecchia1, Luciano Milanesi2, Silvia Scaglione3,4.
Abstract
The culture of progenitor mesenchymal stem cells (MSC) onto osteoconductive materials to induce a proper osteogenic differentiation and mineralized matrix regeneration represents a promising and widely diffused experimental approach for tissue-engineering (TE) applications in orthopaedics. Among modern biomaterials, calcium phosphates represent the best bone substitutes, due to their chemical features emulating the mineral phase of bone tissue. Although many studies on stem cells differentiation mechanisms have been performed involving calcium-based scaffolds, results often focus on highlighting production of in vitro bone matrix markers and in vivo tissue ingrowth, while information related to the biomolecular mechanisms involved in the early cellular calcium-mediated differentiation is not well elucidated yet. Genetic programs for osteogenesis have been just partially deciphered, and the description of the different molecules and pathways operative in these differentiations is far from complete, as well as the activity of calcium in this process. The present work aims to shed light on the involvement of extracellular calcium in MSC differentiation: a better understanding of the early stage osteogenic differentiation program of MSC seeded on calcium-based biomaterials is required in order to develop optimal strategies to promote osteogenesis through the use of new generation osteoconductive scaffolds. A wide spectrum of analysis has been performed on time-dependent series: gene expression profiles are obtained from samples (MSC seeded on calcium-based scaffolds), together with related microRNAs expression and in vivo functional validation. On this basis, and relying on literature knowledge, hypotheses are made on the biomolecular players activated by the biomaterial calcium-phosphate component. Interestingly, a key role of miR-138 was highlighted, whose inhibition markedly increases osteogenic differentiation in vitro and enhance ectopic bone formation in vivo. Moreover, there is evidence that Ca-P substrate triggers osteogenic differentiation through genes (SMAD and RAS family) that are typically regulated during dexamethasone (DEX) induced differentiation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26828589 PMCID: PMC4734718 DOI: 10.1371/journal.pone.0148173
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Experimental Design.
Gene expression experiments were performed in time series (3 replicates for each time point: T0, T5, T10). In vivo tissue formation has been evaluated after 2-4-8 weeks from implantation of seeded biomaterial into the in vivo models (mice).
Cardinality of mRNA Datasets.
| Comparison | Total # DEG | # Annotated | # Up regulated (%) | # Down regulated |
|---|---|---|---|---|
| 375 | 268 | 145 (~55%) | 123 | |
| 257 | 182 | 99 (~55%) | 83 | |
| 53 | 29 | 24 (~83%) | 5 |
For each comparison total number of DEG is reported, together with the amount of annotated genes and the number and percentage of up and down regulated ones.
qPCR results and statistics.
| Genes | T0 samples average | T5 samples average | ΔΔCt | ||
|---|---|---|---|---|---|
| Ct | ΔCt | Ct | ΔCt | ||
| 15,09 | 16,05 | ||||
| 28,21 | 13,12 | 24,51 | 8,46 | 4,66 | |
| 25,28 | 10,19 | 23,67 | 7,62 | 2,57 | |
Results of qPCR experiments for the two selected genes and the considered housekeeping gene. Threshold cycle (Ct) is reported for all genes in T0 and T5 conditions. ΔCt is calculated for both genes in comparison to the housekeeping gene. ΔΔCt indicates differential expression among the two experimental conditions.
Fig 2qPCR results plot.
Barplot showing the average values of the relative gene expression of ITBA2 and ITGB3 genes in 2 biological replicates of T0 (gray bars) and T5 (dark gray bars) samples. Standard deviation is reported above each bar.
Fig 3mRNA Heatmaps.
Heatmaps of differentially expressed genes, obtained using logFC = 2 and pValue<0.05 thresholds, measured for cases A, B and C.
Fig 4Co-occurrence of differential expression.
Venn diagram of co-occurrence of differentially expressed genes (left) and miRNA (right) in cases A, B, C.
DEG Process Analysis.
| Involvement | |||
|---|---|---|---|
| Bone tissue development or pathology onset | (18up+7down) ~9% | (7up+9down) ~9% | (7up) ~24% |
| Calcium aspects | (8up+8down) ~6% | (5up+5 down) ~6% | (1up+1down) ~7% |
| Cell differentiation | (8up+4down) ~4% | (3up+4down) ~4% | (2up) ~7% |
| Extracellular matrix interaction | (11up+9down) ~8% | (9up+11down) ~11% | (5up+1down) ~21% |
| Inflammatory response | (8up+1down) ~3% | (6up+1down) ~4% | (2up) ~7% |
Identification of DEG’ mostly related biological process (considered for each comparison). The complete list of DEG was manually screened relying on Entrez Gene annotations: the most recurrent biological processes were highlighted and genes involved in them were counted in order to obtain statistics.
Functional Annotation Clusters.
| Comparison | Enrichment score |
|---|---|
| Inflammatory response | 9.15 |
| Cell differentiation | 7.54 |
| Bone development | 7.51 |
| Collagen fibril organization | 7.00 |
| Calcium ion binding | 2.58 |
| Bone development | 5.38 |
| Cell differentiation | 5.16 |
| Cell adhesion | 4.29 |
| Inflammatory response | 4.28 |
| Response to calcium ion | 3.00 |
| Inflammatory response | 2.93 |
| Cell differentiation | 2.46 |
| Bone development | 1.73 |
| Calcium ion binding | 1.73 |
Functional annotation clusters related to bone formation have been identified for each comparison. Each cluster is presented with its group enrichment score, which ranks the biological significance of gene groups relying on the geometric mean of EASE scores [64] of terms involved in this cluster.
Fig 5Cell adhesion.
SEM image representing mesenchymal stem cells adhering to the HA surface. Bar is 10 micron.
Up/down-regulated genes grouped into main biological processes.
| Transmembrane transporter | T5 vs. T0 | T10 vs. T0 | T10 vs. T5 |
|---|---|---|---|
| SLC16A6 | 6,05 | 6,40 | |
| SLC7A2 | 3,84 | 2,13 | |
| STC1 | 5,21 | 6,29 | |
| SPON1 | 3,26 | 3,77 | |
| AREG | 3,21 | 2,35 | |
| PLA2G4A | 2,66 | 3,38 | |
| SPP1(OPN) | 3,07 | 4,16 | |
| BMP2 | 4,59 | 5,04 | |
| IBSP (BSP) | 5,92 | 4,07 | |
| PTHLH | 2,21 | 3,33 | |
| BMP6 | 3,57 | 3,54 | |
| COMP | -2,30 | -2,32 | |
| ACAN | -2,09 | -2,80 | |
| PRG4 | 4,82 | -3,12 | |
| ASPN | -2,96 | -3,31 |
DEG evidenced for their involvement into bone-related processes.
Cardinality of miRNA Datasets.
| Comparison | Total # DE miRNA | # Up regulated | # Down regulated |
|---|---|---|---|
| 23 | 16 | 7 | |
| 86 | 85 | 1 | |
| 41 | 1 | 40 |
For each comparison total number of differentially expressed miRNA is reported, together with the amount of annotated miRNA and the number and percentage of up and down regulated ones.
Fig 6miRNA Heatmaps.
Heatmaps of differentially expressed miRNA, obtained using logFC = 1 and pValue<0.05 thresholds, measured for cases A, B and C.
Experimentally Validated microRNA-Target Interactions.
| Comparisons | miRNA with validated targets | Targets in correspondent DEG lists |
|---|---|---|
| hsa-miR-146a-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-132-3p, hsa-miR-34a-5p, hsa-miR-409-3p, hsa-miR-134-5p, hsa-miR-708-5p, hsa-miR-181b-5p, hsa-miR-214-3p | ACSL4, ADAMTSL1, BIRC3, CALD1, CCNA2, CDCP1, CXCR4, DDAH1, FBN1, FRY, IFI44L, IL8, IRAK2, ITGA2, ITGBL1, JAG1. KIF11, LOXL1, MKI67, MMP13, NCAPG, NPR3, PLA2G4A, PTGS2, RAB27B. SLC1A5, SPP1, THBS1, TOP2A, TPM1 | |
| hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-146a-5p, hsa-miR-193b-3p, hsa-miR-29a-3p, hsa-miR-30b-5p, hsa-miR-34a-5p, hsa-miR-146b-5p, hsa-miR-320d, hsa-miR-320e, hsa-miR-16-5p, hsa-miR-130a-3p, hsa-miR-3687, hsa-miR-140-3p, hsa-miR-3648, hsa-miR-425-5p | ANKRD1, ASPM, CA12, CXCR4, DDAH1, EFNB2, IL8, IRAK2, ITGA2, ITGBL1, LMCD1, LMO7, LOXL1, NAMPT, NPR3, PDK4, PLA2G4A, PSAT1, PTGS2, RAB27B, RECK, SFRP2, SLC1A5, SLC38A5, SPP1, STC1, SULF2, THBS1, TNFAIP3, TPM1 | |
| hsa-miR-146a-5p, hsa-miR-138-5p, hsa-miR-193b-3p, hsa-miR-152-3p, hsa-miR-140-3p, hsa-miR-222-3p, hsa-miR-214-3p, hsa-miR-27b-3p, hsa-miR-221-3p, hsa-miR-130b-3p | IL8, MMP1, MMP13, MMP3 |
For each comparison, experimentally validated microRNA-target interactions have been reported, according to miRTarBase database. miRNA presenting validated targets are listed, together with validated targets corresponding to identified DEG.
Differentially Expressed miRNA Concerning Bone Aspects.
| Comparison | miRNA in osteoblasts | miRNA in bone tissue | miRNA in calcium pathway |
|---|---|---|---|
| hsa-miR-1290, hsa-miR-432-5p, hsa-miR-4521 | hsa-miR-146a-5p, hsa-miR-1290, hsa-miR-6126, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-132-3p, hsa-miR-34a-5p, hsa-miR-432-5p, hsa-miR-4521, hsa-miR-181b-5p, hsa-miR-214-3p | hsa-miR-146a-5p, hsa-miR-1290, hsa-miR-619-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-132-3p, hsa-miR-34a-5p, hsa-miR-432-5p, hsa-miR-4521, hsa-miR-134-5p, hsa-miR-708-5p, hsa-miR-181b-5p, hsa-miR-214-3p | |
| hsa-miR-1202,hsa-miR-1207-5p, hsa-miR-1229-5p, hsa-miR-1290, hsa-miR-140-3p, hsa-miR-16-5p, hsa-miR-204-3p, hsa-miR-4417, hsa-miR-4433-3p, hsa-miR-4492, hsa-miR-5739, hsa-miR-575 | hsa-miR-1202, hsa-miR-1207-5p, hsa-miR-1229-5p, hsa-miR-1273g-3p, hsa-miR-1275, hsa-miR-1290, hsa-miR-130a-3p, hsa-miR-140-3p, hsa-miR-146a-5p, hsa-miR-146b-5p, hsa-miR-1587, hsa-miR-16-5p, hsa-miR-193b-3p, hsa-miR-204-3p, hsa-miR-29a-3p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-30d-5p, hsa-miR-34a-5p, hsa-miR-4417, hsa-miR-4433-3p, hsa-miR-4433b-3p, hsa-miR-4459, hsa-miR-4485, hsa-miR-4487, hsa-miR-4492, hsa-miR-4507, hsa-miR-4508, hsa-miR-4521, hsa-miR-4530, hsa-miR-4532, hsa-miR-5739, hsa-miR-575, hsa-miR-6126, hsa-miR-6132, hsa-miR-642a-3p | hsa-miR-1202, hsa-miR-1207-5p, hsa-miR-1273g-3p, hsa-miR-1275, hsa-miR-1290, hsa-miR-130a-3p, hsa-miR-140-3p, hsa-miR-146a-5p, hsa-miR-146b-5p, hsa-miR-16-5p, hsa-miR-193b-3p, hsa-miR-204-3p, hsa-miR-29a-3p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-30d-5p, hsa-miR-320d, hsa-miR-320e, hsa-miR-34a-5p, hsa-miR-3648, hsa-miR-3687, hsa-miR-425-5p, hsa-miR-4417, hsa-miR-4433-3p, hsa-miR-4433b-3p, hsa-miR-4459, hsa-miR-4485, hsa-miR-4487, hsa-miR-4492, hsa-miR-4507, hsa-miR-4508, hsa-miR-4521, hsa-miR-4530, hsa-miR-4532, hsa-miR-4649-5p, hsa-miR-5739, hsa-miR-575, hsa-miR-6085, hsa-miR-6124, hsa-miR-6132, hsa-miR-619-5p, hsa-miR-642a-3p | |
| hsa-miR-1202, hsa-miR-1207-5p, hsa-miR-1229-5p, hsa-miR-152-3p, hsa-miR-221-3p, hsa-miR-432-5p, hsa-miR-4492 | hsa-miR-1202, hsa-miR-1207-5p, hsa-miR-1229-5p, hsa-miR-130b-3p, hsa-miR-138-5p, hsa-miR-140-3p, hsa-miR-146a-5p, hsa-miR-1587, hsa-miR-193b-3p, hsa-miR-214-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-432-5p, hsa-miR-4487, hsa-miR-4492, hsa-miR-4507, hsa-miR-4530, hsa-miR-6126, hsa-miR-6132, hsa-miR-642a-3p | hsa-miR-1202, hsa-miR-1207-5p, hsa-miR-130b-3p, hsa-miR-138-5p, hsa-miR-140-3p, hsa-miR-146a-5p, hsa-miR-152-3p, hsa-miR-193b-3p, hsa-miR-214-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-27b-3p, hsa-miR-432-5p, hsa-miR-4487, hsa-miR-4492, hsa-miR-4507, hsa-miR-4530, hsa-miR-6132, hsa-miR-642a-3p |
For each comparison, differentially expressed miRNA concerning bone tissue related processes are reported, according to data maintained into miRWalk database.
Involvement of enrichment genes into developmental and immune system processes.
| 169 | 17.2 | |
| 95 | 21.3 | |
| 27 | 30.3 | |
| 99 | 10.1 | |
| 66 | 14.8 | |
| 18 | 20.2 | |
PPI genes obtained from gProfiler were analyzed through Panther tool and functional involvement into developmental and immune system processes is reported for each comparison.
Fig 7Haematoxylin-eosin staining and IHC.
HE analyses have been performed on samples harvested after 2 (panel A) and 8 weeks (panel B) of implantations in in-vivo models, reporting different levels of bone matrix deposition. Ob = osteoblasts, oc = osteocytes, bv = blood vessels. Panel C reports IHC analyses performed after 8 weeks of implantation. IHC expresses intracellular pro-collagen coloured in red, while blue cells (i.e. negative) were obtained after counterstaining with haematoxylin. Bars are 50 micron.
Differentially Expressed genes Concerning RAS pathway.
| T5 vs. T0 | T10 vs. T0 | |
|---|---|---|
| RASD1 | 3,75 | 4,03 |
| TMEM158 | 3,32 | 3,02 |
| RAB27B | 5,01 | 5,60 |
| RASEF | 2,57 | 3,40 |
DEG evidenced for their involvement into RAS pathway.